Avicanna to Participate in the Lytham Partners Winter 2021 Investor Conference
December 10 2021 - 7:30AM
Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX:
AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the
development, manufacturing, and commercialization of plant-derived
cannabinoid-based products, announced today it will be
participating in the Lytham Partners Winter 2021 Investor
Conference taking place from December 13-16, 2021. During the
event, the company will be participating in a webcasted Fireside
Chat discussing its vision for 2022 and conducting 1x1 virtual
investor meetings.
The webcasted Fireside Chat will be available for
viewing at 11:00am ET on Monday, December 13, 2021, on
https://wsw.com/webcast/lytham3/avi/1858880. The webcast will also
be available for replay following the event. To arrange a 1x1
meeting with management, please contact Lytham Partners at
1x1@lythampartners.com or register at
www.lythampartners.com/winter2021invreg.
About Avicanna
Avicanna is a Canadian commercial-stage
biopharmaceutical company established in cannabinoid research,
development, and evidence-based products for the global consumer,
as well as medical and pharmaceutical market segments. In leading
global cannabinoid advancements, Avicanna conducts most of its
research in Canada at its R&D headquarters in the Johnson &
Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS
Discovery District. The company actively collaborates with leading
Canadian academic and medical institutions. Avicanna has
established an industry-leading scientific platform including
advanced R&D and clinical development which has led to the
commercialization of over twenty products across four main market
segments:
- Medical Cannabis
& Wellness Products: Marketed under the RHO Phyto™ brand, or
Magisterial Preparations, these medical and wellness products are
an advanced line of pharmaceutical-grade cannabis products
containing varying ratios of cannabidiol (“CBD”) and
tetrahydrocannabinol (“THC”). The product portfolio contains a full
formulary of products including oral, sublingual, topical, and
transdermal deliveries that have controlled dosing, enhanced
absorption and stability studies supported by pre-clinical data.
The advanced formulary is marketed with consumer, patient and
medical community education and training. Avicanna’s medical and
wellness product portfolio also forms the foundation of the
Company’s pharmaceutical pipeline with the contribution of the
formulations that form the basis of the products as well as the
data generated from sales and participation of the products in real
world evidence studies.
- CBD
Derma-Cosmetic Products: Marketed under the Pura H&W™ or Pura
Earth™ brands, these registered, clinically tested, derma-cosmetic
products include a portfolio of functional CBD topical
products.
- Pharmaceutical
Pipeline: Leveraging Avicanna’s scientific platform, vertical
integration, and real-world evidence, Avicanna has created a
pipeline of patent-pending drug candidates which are
indication-specific and in various stages of clinical development
and commercialization. These cannabinoid-based drug candidates
provide solutions for unmet medical needs in the areas of
dermatology, chronic pain, and various neurological disorders.
Avicanna’s first pharmaceutical preparation (Trunerox) is in the
drug registration stage in South America.
- Cannabis Raw
Materials, Seeds, and Bulk Formulations: Marketed under the Aureus™
brand, the Company’s raw material business has successfully
completed sales to 11 countries. Aureus offers cannabis dried
flower, standardized seeds, full spectrum extracts, and cannabinoid
distillates, isolated cannabinoids (CBD, THC, cannabigerol (“CBG”)
and other rare cannabinoids), and bulk formulations derived from
hemp and cannabis cultivars through its sustainable, economical,
and industrial-scale subsidiaries based in Colombia. The majority
of the Aureus products are produced at Santa Marta Golden Hemp
S.A.S. (“SMGH”), the Company’s majority-owned subsidiary, which is
also Good Agricultural and Collection Practices (“GACP”) certified
and has United States Department of Agriculture (“USDA”) National
Organic Program certification for its hemp cultivar.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit www.avicanna.com,
contact Ivana Maric by email at info@avicanna.com or follow us on
social media on Linkedin, Twitter, Facebook or Instagram.
The Company posts updates through videos from the official
company YouTube channel
https://www.youtube.com/channel/UCFXPBGdKSxOUOf_VZoSFSUA.
Cautionary Note Regarding
Forward-Looking Information and Statements
This news release contains "forward-looking
information" within the meaning of applicable securities laws.
Forward-looking information contained in this press release may be
identified by the use of words such as, "may", "would", "could",
"will", "likely", "expect", "anticipate", "believe, "intend",
"plan", "forecast", "project", "estimate", "outlook" and other
similar expressions. Forward-looking information is not a
guarantee of future performance and is based upon a number of
estimates and assumptions of management in light of management's
experience and perception of trends, current conditions and
expected developments, as well as other factors relevant in the
circumstances, including assumptions in respect of current and
future market conditions, the current and future regulatory
environment, the availability of licenses, approvals and permits,
and the utility and application of certain drugs and products.
Although the Company believes that the expectations and assumptions
on which such forward looking information is based are reasonable,
undue reliance should not be placed on the forward looking
information because the Company can give no assurance that they
will prove to be correct. Actual results and developments may
differ materially from those contemplated by these statements.
Forward-looking information is subject to a variety of risks and
uncertainties that could cause actual events or results to differ
materially from those projected in the forward-looking information.
Such risks and uncertainties include, but are not limited to
current and future market conditions, including the market price of
the common shares of the Company, and the risk factors set out in
the Company's annual information form dated September 3, 2021 and
final short form prospectus dated November 27, 2020, filed with the
Canadian securities regulators and available under the Company's
profile on SEDAR at www.sedar.com. The statements in this press
release are made as of the date of this release. The Company
disclaims any intent or obligation to update any forward-looking
information, whether as a result of new information, future events
or results or otherwise, other than as required by applicable
securities laws.
Avicanna (TSX:AVCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avicanna (TSX:AVCN)
Historical Stock Chart
From Sep 2023 to Sep 2024